MedTrace Logo

Investigation of Sleep Quality and Prevalence of Sleep-disordered Breathing in Children and Young People With Epilepsy

NCT03103841 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2023-03-28

No results posted yet for this study

Summary

Obstructive sleep apnoea (OSA) is a condition that affects around one in 20 children. In children with OSA, repeated episodes of airway obstruction can severely disturb and fragment sleep, leading to subsequent cognitive and behavioural problems .

Epilepsy affects 60,000 children in the UK and up to 30% of children with epilepsy have learning problems. Evidence suggests that OSA is more common in children with epilepsy, such that sleep disturbance could account for some of the learning problems they experience.

The aim of this study is to determine the prevalence of OSA in children with epilepsy. The investigators plan carry out detailed sleep studies in children with epilepsy and healthy controls to determine if children with epilepsy are more likely to have OSA than healthy children of the same age.

OSA is almost always treatable and the benefits of detecting and treating the condition in healthy children are well-established. If OSA proves to be a common finding in children with epilepsy, it will be important to carry out further studies to see if treating the condition has beneficial effects on learning and behaviour. This project could lead doctors to target sleep-disordered breathing as a way of improving learning outcomes in children with epilepsy.

Conditions

Interventions

PROCEDURE

Sleep studies [Polysomnography]

Undertaking of sleep measurements by polysomnography and use of validated sleep questionnaires

Sponsors & Collaborators

  • Action Medical Research

    collaborator OTHER

  • University of Edinburgh

    collaborator OTHER

  • NHS Lothian

    lead OTHER_GOV

Principal Investigators

  • Don S Urquhart, MD, FRCPCH · NHS Lothian

Eligibility

Min Age
5 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-31
Primary Completion
2022-10-31
Completion
2022-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03103841 on ClinicalTrials.gov